Maze Therapeutics, Inc. Common Stock (MAZE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has a cash flow conversion efficiency ratio of -0.033x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.05 Million) by net assets ($453.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MAZE company net worth for the company's overall valuation and market capitalisation.
Maze Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Maze Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore Maze Therapeutics, Inc. Common Stock cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cansino Biologics Inc
SHG:688185
|
0.003x |
|
Rianlon Corp
SHE:300596
|
0.066x |
|
DOMS Industries Limited
NSE:DOMS
|
0.046x |
|
Norwegian Air Shuttle ASA
OL:NAS
|
1.090x |
|
Sally Beauty Holdings Inc
NYSE:SBH
|
0.129x |
|
Fangda Special Steel Technology Co Ltd
SHG:600507
|
0.015x |
|
Adecoagro SA
NYSE:AGRO
|
-0.001x |
|
Ujjivan Small Finance Bank Limited
NSE:UJJIVANSFB
|
-0.110x |
Annual Cash Flow Conversion Efficiency for Maze Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Maze Therapeutics, Inc. Common Stock from 2022 to 2025. View MAZE stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $354.97 Million | $-111.94 Million | -0.315x | -181.75% |
| 2024-12-31 | $196.90 Million | $75.95 Million | 0.386x | +104.47% |
| 2023-12-31 | $10.05 Million | $-86.83 Million | -8.636x | -783.11% |
| 2022-12-31 | $101.44 Million | $-99.20 Million | -0.978x | -- |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral s… Read more